Novo Nordisk A/s

Sanquin Blood Supply Foundation

Stichting Sanquin Bloedvoorziening

Laust Bruun Johnsen

Ole Hvilsted Olsen

Koenraad Mertens

Henning Ralf Stennicke

Peder Lisby Noerby

Kasper Lamberth

Henriet Meems

Alexander Benjamin Meijer

Johannes Jacobus Voorberg

Maartje Van Den Biggelaar

Henrik Oestergaard

Jianhe Chen

Prafull S Gandhi

Rong Zhou

Karina Thorn

Per J Greisen

Marianne Hjortnes Kjalke

Mikkel Nors Harndahl

Bjarne Gram Hansen

Zhiru Yang

Morten Groenbech Rasch

Haisun Zhu

Ida Hilden

Anders Svensson

Thomas Dock Steenstrup

Gert Bolt

Eva Johansson

Marianne Hjortnæs Kjalke

The present invention relates to improved procoagulant antibodies including bispecific antibodies capable of binding to coagulation Factor IX (FIX) or the activated form thereof Factor IXa (FIXa) and optionally Factor X (FX) and the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A.

Procoagulant antibodies

The present invention relates to multispecific procoagulant antibodies capable of binding to coagulation Factor IX (FIX) and/or the activated form thereof Factor IXa (FIXa), and Factor X (FX) and/or the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes or parts thereof and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A as well as kits, methods of manufacture and methods of use.

The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.

Factor VIII variants having a decreased cellular uptake

The invention relates to a method for the production of a Factor VIII polypeptide, the method comprising the steps of a) culturing a mammalian cell expressing a Factor VIII polypeptide under conditions for expression of said Factor VIII polypeptide, said culturing conditions involving a cell culture medium comprising a C2-domain ligand, and b) isolating the expressed Factor VIII polypeptide from the mammalian cell by suitable means.

Factor VIII polypeptide titers in cell cultures

Growing community of inventors

Skodsborg, Denmark

Laust Bruun Johnsen